Jason Rhodes Sells 24,100 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 24,100 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $21.10, for a total transaction of $508,510.00. Following the sale, the director directly owned 1,081,044 shares of the company’s stock, valued at $22,810,028.40. This represents a 2.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Up 1.6%

Shares of NASDAQ DYN opened at $20.94 on Friday. The company’s 50 day moving average price is $18.45 and its 200-day moving average price is $18.11. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00. The company has a market capitalization of $3.46 billion, a P/E ratio of -6.50 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the company posted ($1.05) EPS. Equities analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Analyst Ratings Changes

DYN has been the subject of several recent research reports. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. TD Cowen began coverage on Dyne Therapeutics in a report on Friday. They set a “buy” rating for the company. Sanford C. Bernstein increased their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Creative Planning grew its position in Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after buying an additional 1,440 shares in the last quarter. Hilton Head Capital Partners LLC purchased a new position in shares of Dyne Therapeutics in the 1st quarter worth approximately $26,000. Caxton Associates LLP boosted its stake in shares of Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after buying an additional 1,627 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.